HRP20010762A2 - Renin inhibitors - Google Patents

Renin inhibitors

Info

Publication number
HRP20010762A2
HRP20010762A2 HR20010762A HRP20010762A HRP20010762A2 HR P20010762 A2 HRP20010762 A2 HR P20010762A2 HR 20010762 A HR20010762 A HR 20010762A HR P20010762 A HRP20010762 A HR P20010762A HR P20010762 A2 HRP20010762 A2 HR P20010762A2
Authority
HR
Croatia
Prior art keywords
renin inhibitors
renin
inhibitors
Prior art date
Application number
HR20010762A
Other languages
English (en)
Inventor
Breu Volker
Maerki Hans-Peter
Vieira Eric
Wostl Wolfgang
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20010762A2 publication Critical patent/HRP20010762A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
HR20010762A 1999-04-27 2001-10-19 Renin inhibitors HRP20010762A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108199 1999-04-27
PCT/EP2000/003555 WO2000064873A1 (en) 1999-04-27 2000-04-19 Renin inhibitors

Publications (1)

Publication Number Publication Date
HRP20010762A2 true HRP20010762A2 (en) 2005-02-28

Family

ID=8238050

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010762A HRP20010762A2 (en) 1999-04-27 2001-10-19 Renin inhibitors

Country Status (35)

Country Link
US (2) US6376672B1 (cs)
EP (1) EP1175400B1 (cs)
JP (1) JP3808706B2 (cs)
KR (1) KR100443684B1 (cs)
CN (1) CN1147471C (cs)
AR (2) AR018719A1 (cs)
AT (1) ATE512949T1 (cs)
AU (1) AU763718B2 (cs)
BR (1) BR0010080B1 (cs)
CA (1) CA2370888C (cs)
CO (1) CO5170513A1 (cs)
CZ (1) CZ302012B6 (cs)
DK (1) DK1175400T3 (cs)
EG (1) EG23979A (cs)
ES (1) ES2366668T3 (cs)
GC (1) GC0000251A (cs)
HK (1) HK1045999B (cs)
HR (1) HRP20010762A2 (cs)
HU (1) HU227764B1 (cs)
IL (2) IL146002A0 (cs)
JO (1) JO2256B1 (cs)
MA (1) MA26787A1 (cs)
MX (1) MXPA01010934A (cs)
MY (1) MY127894A (cs)
NO (1) NO320803B1 (cs)
NZ (1) NZ514981A (cs)
PE (1) PE20010069A1 (cs)
PL (1) PL199895B1 (cs)
PT (1) PT1175400E (cs)
RS (1) RS51156B (cs)
RU (1) RU2213731C2 (cs)
TR (1) TR200103095T2 (cs)
TW (1) TWI224593B (cs)
WO (1) WO2000064873A1 (cs)
ZA (1) ZA200108735B (cs)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6835686B2 (en) * 2001-07-05 2004-12-28 Millennium Specialty Chemicals Catalyst system and process for rearrangement of epoxides to allylic alcohols
AU2003229746A1 (en) * 2002-06-27 2004-01-19 Actelion Pharmaceuticals Ltd Novel tetrahydropyridine derivatives as renin inhibitors
US20040214832A1 (en) * 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
MXPA05011478A (es) * 2003-04-29 2005-12-12 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,6-tetrahidropiridina 3,4-disustituidos novedosos.
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
RU2374228C2 (ru) 2003-11-26 2009-11-27 Новартис Аг Производные 4-фенилпиперидина в качестве ингибиторов ренина
TW200613274A (en) * 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
PT1799199E (pt) 2004-10-08 2012-07-03 Novartis Ag Uso de inibidores da renina para a prevenção ou tratamento da disfunção diastólica ou insuficiência cardíaca diastólica
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
CN101151262B (zh) * 2005-03-31 2011-07-06 斯皮德尔实验股份公司 取代的哌啶
JP2008535825A (ja) * 2005-03-31 2008-09-04 シュペーデル・エクスペリメンタ・アーゲー レニン阻害剤としての３，４，５−置換ピペリジン
EP1897879A3 (en) * 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
TW200833687A (en) * 2005-03-31 2008-08-16 Speedel Experimenta Ag Substituted piperidines
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
NZ564689A (en) 2005-05-27 2011-02-25 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007048027A2 (en) * 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
CN101356156B (zh) * 2005-11-14 2012-12-05 生命医药公司 天冬氨酸蛋白酶抑制剂
AR058885A1 (es) * 2005-12-30 2008-02-27 Novartis Ag Compuestos de piperidina 3,5-sustituidos
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
AU2008267287B2 (en) 2007-06-25 2012-02-16 Novartis Ag N5-(2-ethoxyethyl)-N3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
WO2009056617A2 (en) * 2007-11-02 2009-05-07 Novartis Ag 4,4-disubstituted piperdines as renin inhibitors
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2488661B1 (en) 2009-10-14 2014-12-24 Oberbauer, Rainer Acute kidney injury risk testing
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK231088D0 (da) 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
AU657912B2 (en) 1991-06-24 1995-03-30 Enraf-Nonius B.V. Device for measuring the respiration of a person
AU6735396A (en) 1995-07-24 1997-02-18 Railfix N.V. Electrical permanent-magnet system for manoeuvring a magnetic, particularly a ferromagnetic, load
EP0863875B1 (de) * 1995-09-07 2003-06-04 F. Hoffmann-La Roche Ag Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
AU9740998A (en) * 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
CN1349503A (zh) 2002-05-15
RU2213731C2 (ru) 2003-10-10
GC0000251A (en) 2006-11-01
CA2370888A1 (en) 2000-11-02
AU763718B2 (en) 2003-07-31
EG23979A (en) 2008-02-27
RS51156B (sr) 2010-10-31
AR070473A2 (es) 2010-04-07
TR200103095T2 (tr) 2002-04-22
CZ302012B6 (cs) 2010-09-08
HU227764B1 (en) 2012-02-28
NO20015206L (no) 2001-10-25
ATE512949T1 (de) 2011-07-15
CA2370888C (en) 2005-08-23
PL199895B1 (pl) 2008-11-28
EP1175400B1 (en) 2011-06-15
CN1147471C (zh) 2004-04-28
US6376672B1 (en) 2002-04-23
AU4296800A (en) 2000-11-10
JP3808706B2 (ja) 2006-08-16
NO20015206D0 (no) 2001-10-25
MXPA01010934A (es) 2002-05-06
NZ514981A (en) 2004-02-27
YU77101A (sh) 2004-09-03
WO2000064873A1 (en) 2000-11-02
NO320803B1 (no) 2006-01-30
JP2002543063A (ja) 2002-12-17
IL146002A0 (en) 2002-07-25
US6673931B2 (en) 2004-01-06
HK1045999B (zh) 2004-10-21
CZ20013854A3 (cs) 2002-04-17
MA26787A1 (fr) 2004-12-20
US20020087002A1 (en) 2002-07-04
TWI224593B (en) 2004-12-01
EP1175400A1 (en) 2002-01-30
BR0010080B1 (pt) 2012-03-20
HUP0203669A2 (hu) 2003-02-28
HUP0203669A3 (en) 2003-12-29
KR20010109529A (ko) 2001-12-10
BR0010080A (pt) 2002-01-15
HK1045999A1 (en) 2002-12-20
MY127894A (en) 2006-12-29
IL146002A (en) 2007-03-08
ES2366668T3 (es) 2011-10-24
ZA200108735B (en) 2003-01-23
AR018719A1 (es) 2001-11-28
PT1175400E (pt) 2011-08-11
KR100443684B1 (ko) 2004-08-09
PE20010069A1 (es) 2001-03-03
CO5170513A1 (es) 2002-06-27
JO2256B1 (en) 2004-10-07
PL353442A1 (en) 2003-11-17
DK1175400T3 (da) 2011-07-18

Similar Documents

Publication Publication Date Title
EG23979A (en) Renin inhibitors
GB9900416D0 (en) Inhibitors
PL362903A1 (en) Renin inhibitors
IL148820A0 (en) Fab i inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
HK1044935A1 (zh) 雙異取代的金屬蛋白酶抑制劑
EP1235577A4 (en) PROTEASE INHIBITORS
EP1153022A4 (en) PROTEASE INHIBITORS
GB9924522D0 (en) Enzyme inhibitors
EP1232155A4 (en) PROTEASE INHIBITORS
EP1229912A4 (en) PROTEASE INHIBITORS
EP1229914A4 (en) PROTEASE INHIBITORS
EP1229915A4 (en) PROTEASE INHIBITORS
EP1231921A4 (en) PROTEASE INHIBITORS
HK1043534A1 (zh) 蛋白酶抑制劑
EP1173429A4 (en) PROTEASE INHIBITORS
EP1233771A4 (en) PROTEASE INHIBITORS
EP1351930A4 (en) PROTEASE INHIBITORS
EP1229911A4 (en) PROTEASE INHIBITORS
EP1231923A4 (en) PROTEASE INHIBITORS
GB2389113B (en) B-secretase inhibitor
EP1232154A4 (en) PROTEASE INHIBITORS
EP1231922A4 (en) PROTEASE INHIBITORS
GB9929341D0 (en) Inhibitors
GB9929340D0 (en) Inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
NPPZ Continued processing
NPPU Continued processing adopted
ODBI Application refused